HTI-1403

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameHTI-1403

Drug Alias NameADC program (Shanghai Hengrui Pharmaceutical)HTI-1403SHR-152852

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionNerve growth factor receptor Trk-A inhibitorsAnticancer protein kinase inhibitors

TargetsNerve growth factor receptor Trk-A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShanghai Hengrui Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A